

01-05-01

A

01/04/01
JC661 U.S. PTO

PATENT
JC662 U.S. PTO
09/754723
01/04/01

Attorney Docket No.: 3745.224 US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Commissioner for Patents
Washington, DC 20231

Express Mail Label No. EL636737258US
Date of Deposit January 4, 2001

Sir:

This is a request for filing a **continuation** application under 37 C.F.R. 1.53(b)
of

Applicant(s): Efendic et al

Title: Use Of A Peptide

15 pages of specification 0 sheets of Formal Drawings

2 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee: \$710.00

Total Claims: 6 - 20 = 0 x 18 = \$-0-

Independent Claims: 0 - 3 = 0 x 80 = \$-0-

Total Fee: \$710.00

Priority of Danish application no. 0363/92 filed on March 19, 1992 is claimed under 35 U.S.C. 119. A certified copy was filed with U.S. Serial No. 08/295,913 filed on September 15, 1994.

The benefit of application nos. 08/842,121 filed on April 23, 1997 and 08/295,913 filed on October 13, 1994 and PCT/DK93/00099 filed on March 18, 1993 in the U.S. is claimed under 35 U.S.C. 120.


Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

00754723-010401

Please charge the required fee, estimated to be \$710, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: January 4, 2001


Valeta A. Gregg, Reg. No. 35,127
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

PATENT

EXPRESS MAIL CERTIFICATE

Re: U.S. Patent Application for
Title: Use Of A Peptide
Applicants: Efendic et al

Date of Deposit: January 4, 2001

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Copy of Executed Combined Declaration and Power of Attorney
4. Preliminary Amendment
5. Information Disclosure Statement
6. Form PTO-1449

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, DC 20231.

Sylvia Gonzalez
(Name of person mailing paper(s) or fee)

(Signature of person mailing paper(s) or fee)

Mailing Address:
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212)867-0123